Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.

[1]  J. Messenger,et al.  Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[2]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[3]  J. McMurray,et al.  Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual‐level reanalysis of CORONA and GISSI‐HF , 2015, European journal of heart failure.

[4]  M. Gheorghiade,et al.  Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes , 2014, Current Heart Failure Reports.

[5]  R. Califf,et al.  Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. , 2014, American heart journal.

[6]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[7]  M. Vaduganathan,et al.  Lipids, statins, and clinical outcomes in heart failure: rethinking the data , 2014, Heart Failure Reviews.

[8]  S. Ebrahim,et al.  WITHDRAWN: Reduced dietary salt for the prevention of cardiovascular disease. , 2013, The Cochrane database of systematic reviews.

[9]  M. Vaduganathan,et al.  Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). , 2013, The American journal of cardiology.

[10]  Jennifer G. Robinson,et al.  Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. , 2013, Journal of the American Pharmacists Association : JAPhA.

[11]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[12]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[13]  R. Califf,et al.  An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. , 2010, American heart journal.

[14]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[15]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[16]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[17]  J. Rouleau,et al.  Navigating the Crossroads of Coronary Artery Disease and Heart Failure , 2006, Circulation.

[18]  M. Pfeffer,et al.  An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. , 2004, European heart journal.

[19]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[20]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[21]  C M O'Connor,et al.  Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. , 1997, Journal of the American College of Cardiology.